Desjardins Global Asset Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Desjardins Global Asset Management’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	$24.9K	Buy	77 +2	+3%	+$627	﹤0.01%	587
2023 Q3	$26.9K	Sell	75 -75	-50%	-$28.9K	﹤0.01%	584
2023 Q2	$56.8K	Buy	150 +76	+103%	+$30.9K	0.01%	525
2023 Q1	$35K	Buy	+74	New	+$34.6K	﹤0.01%	537
2022 Q4	–	Sell	-1,438	Closed	-$600K	–	484
2022 Q3	$600K	Hold	1,438	–	–	0.08%	207
2022 Q2	$712K	Sell	1,438 -807	-36%	-$420K	0.09%	189
2022 Q1	$1.26M	Sell	2,245 -279	-11%	-$168K	0.11%	172
2021 Q4	$1.91M	Buy	+2,524	New	+$1.89M	0.16%	151

Other funds holding BIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VAM

Veritas Asset Management London, United Kingdom $5.9B AUM 3.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Desjardins Global Asset Management's BIO Position: Q4 2023 in Review

Desjardins Global Asset Management increased its Bio-Rad Laboratories Class A (BIO) stake by 2.7% in Q4 2023, buying an estimated $627 and bringing the position to 77 shares worth $24.9K. The position accounts for ﹤0.01% of the portfolio, ranked #587.

Desjardins Global Asset Management first reported a position in BIO in Q4 2021 and has held it in 8 quarters since. The position peaked at $1.91M in Q4 2021. 483 funds tracked by Wall St. Rank hold BIO as of Q4 2023.

Desjardins Global Asset Management held 77 shares of Bio-Rad Laboratories Class A worth $24.9K as of Q4 2023.
Desjardins Global Asset Management bought 2 Bio-Rad Laboratories Class A shares in Q4 2023, an estimated $627.
Bio-Rad Laboratories Class A made up ﹤0.01% of Desjardins Global Asset Management's portfolio in Q4 2023, its #587 holding.
Desjardins Global Asset Management first reported a position in Bio-Rad Laboratories Class A in Q4 2021 and has held it in 8 quarters since.
Desjardins Global Asset Management's Bio-Rad Laboratories Class A position peaked at $1.91M in Q4 2021.
483 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q4 2023.

Based on Desjardins Global Asset Management's 13F filing for Q4 2023, filed 30 Jan 2024.